Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

CRISPR Biotech Intellia Plummets as Trial Paused for Safety

Enrollment and dosing halted after a severe liver enzyme spike hospitalized a patient; over 697 participants were enrolled before the pause, Intellia said.

Summary by Pharmaphorum
Intellia lost 45% of its value today as phase 3 trials of one of its priority drug programmes were halted due to a patient being hospitalised.

2 Articles

PharmaphorumPharmaphorum
Center

CRISPR biotech Intellia plummets as trial paused for safety

Intellia lost 45% of its value today as phase 3 trials of one of its priority drug programmes were halted due to a patient being hospitalised.

Read Full Article
biopharmadive.combiopharmadive.com
Center

Intellia pauses two CRISPR drug studies after safety scare

A study volunteer receiving Intellia’s transthyretin amyloidosis treatment was hospitalized due to severe signs of liver stress, prompting the company to pause enrollment and dosing while evaluating a new safety protocol.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

biopharmadive.com broke the news in on Monday, October 27, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

CRISPR icon

CRISPR

News
For You
SearchBlindspotLocal